Flamel Technologies, Inc

info@flamel.com

Company

Technologies and Products

Investor Relations

Press Releases

Contact

Nicolas Flamel (1330-1418)
was a French alchemist
in the Middle Ages...
learn more

Flamel Technologies is a drug delivery company with expertise in polymer chemistry.

The company was founded in 1990.

In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq.

The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns cGMP pharmaceutical production facility of over 100,000 square feet located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules).

Flamel’s drug delivery platforms, Medusa® for therapeutic proteins and peptides, and Micropump® for small molecules , have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs.

The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.

Flamel has partnership agreements with major pharmaceutical companies:

The Company is actively seeking partnership agreements for the development and commercialization of products currently in its pipeline as well as for new products using Flamel’s proprietary delivery systems.

Latest News

Flamel Technologies Corporate Presentation - June 2009
To view the latest presentation, click here.

June 25, 2009
Flamel Technologies Announces Two New Feasibility Agreements

June 24, 2009
Flamel Technologies Announces Results of Annual Meeting

June 22, 2009
Flamel Technologies Announces New Feasibility Projects; Technology Access Fee

May 11, 2009
Flamel Technologies Announces Profitable First Quarter Results; Increased Cash Levels
Conference Call
Participant Dial In (Toll Free): 1-800-860-2442
International Dial In: +1 412-858-4600
ID: 430430
Webcast

March 20, 2009
Flamel Technologies to Receive $4 Million Milestone Payment from GlaxoSmithKline

March 4, 2009
Flamel Technologies Announces Fourth Quarter and Year-End 2008 Results
Conference Call Webcast

February 23, 2009
Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer

February 17, 2009
Flamel Technologies Announces Merck Serono's Exercise of Option to License Medusa Technology of Development of an Extended-Release Formulation of a Therapeutic Protein

Latest News

Medusa ®

Micropump ® Technologies

June 25, 2009
Flamel Technologies Announces Two New Feasibility Agreements

June 24, 2009
Flamel Technologies Announces Results of Annual Meeting

June 22, 2009
Flamel Technologies Announces New Feasibility Projects; Technology Access Fee

May 05, 2009
Flamel Technologies Announces Projected Release Date of First Quarter Results; Conference Call

March 20, 2009
Flamel Technologies to Receive $4 Million Milestone Payment from GlaxoSmithKline

March 4, 2009
Flamel Technologies Announces Fourth Quarter and Year-End 2008 Results
Conference Call Webcast

February 24, 2009
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

February 17, 2009
Flamel Technologies Announces Merck Serono's Exercise of Option to License Medusa Technology of Development of an Extended-Release Formulation of a Therapeutic Protein Conference Call Webcast

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info